Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization.

Publisher: Public Library of Science Country of Publication: United States NLM ID: 101238921 Publication Model: eCollection Cited Medium: Internet ISSN: 1553-7374 (Electronic) Linking ISSN: 15537366 NLM ISO Abbreviation: PLoS Pathog Subsets: MEDLINE

Original Publication: San Francisco, CA : Public Library of Science, c2005-

COVID-19* ; Single-Domain Antibodies*/pharmacology; Humans ; SARS-CoV-2 ; Epitopes ; Spike Glycoprotein, Coronavirus ; Antibodies, Neutralizing/pharmacology ; Antibodies, Viral

The continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increased transmissibility and profound immune-escape capacity makes it an urgent need to develop broad-spectrum therapeutics. Nanobodies have recently attracted extensive attentions due to their excellent biochemical and binding properties. Here, we report two high-affinity nanobodies (Nb-015 and Nb-021) that target non-overlapping epitopes in SARS-CoV-2 S-RBD. Both nanobodies could efficiently neutralize diverse viruses of SARS-CoV-2. The neutralizing mechanisms for the two nanobodies are further delineated by high-resolution nanobody/S-RBD complex structures. In addition, an Fc-based tetravalent nanobody format is constructed by combining Nb-015 and Nb-021. The resultant nanobody conjugate, designated as Nb-X2-Fc, exhibits significantly enhanced breadth and potency against all-tested SARS-CoV-2 variants, including Omicron sub-lineages. These data demonstrate that Nb-X2-Fc could serve as an effective drug candidate for the treatment of SARS-CoV-2 infection, deserving further in-vivo evaluations in the future.
Competing Interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: J.Y., S.L. and G.L. have a patent on anti-RBD nanobodies described herein. X.L. and B.C. are employees of CHENGDU NB BIOLAB CO., LTD. The other authors have declared that no competing interests exist.
(Copyright: © 2023 Yang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)

Nat Rev Immunol. 2023 Mar;23(3):189-199. (PMID: 36168054)
Signal Transduct Target Ther. 2021 Sep 16;6(1):343. (PMID: 34531369)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
J Med Virol. 2022 Mar;94(3):847-857. (PMID: 34609003)
N Engl J Med. 2021 Nov 18;385(21):1941-1950. (PMID: 34706189)
Cell. 2022 Oct 13;185(21):3992-4007.e16. (PMID: 36198317)
Rev Med Virol. 2022 Sep;32(5):e2381. (PMID: 35856385)
Proc Natl Acad Sci U S A. 2022 Aug 2;119(31):e2205412119. (PMID: 35858383)
Front Immunol. 2017 Nov 22;8:1603. (PMID: 29213270)
Nat Struct Mol Biol. 2021 Feb;28(2):202-209. (PMID: 33432247)
Cell. 2021 May 27;184(11):2939-2954.e9. (PMID: 33852911)
Sci Adv. 2021 May 26;7(22):. (PMID: 34039613)
Acta Crystallogr D Biol Crystallogr. 1994 Sep 1;50(Pt 5):760-3. (PMID: 15299374)
Cell. 2022 Jul 7;185(14):2422-2433.e13. (PMID: 35772405)
Nature. 2020 Aug;584(7819):120-124. (PMID: 32454512)
Nature. 2021 Jul;595(7869):718-723. (PMID: 34082438)
Front Immunol. 2022 May 18;13:820336. (PMID: 35663966)
Cell Res. 2022 Sep;32(9):831-842. (PMID: 35906408)
Signal Transduct Target Ther. 2022 Feb 21;7(1):56. (PMID: 35190526)
Nat Rev Microbiol. 2021 Nov;19(11):685-700. (PMID: 34535791)
Nature. 2021 May;593(7859):424-428. (PMID: 33767445)
Biomed Res Int. 2017;2017:5479762. (PMID: 29250543)
Nat Rev Immunol. 2021 Jun;21(6):382-393. (PMID: 33875867)
J Biol Chem. 2021 Oct;297(4):101202. (PMID: 34537245)
Immunology. 2020 Sep;161(1):53-65. (PMID: 32506493)
Cell. 2021 Apr 1;184(7):1804-1820.e16. (PMID: 33691139)
Cell Rep Med. 2023 Feb 21;4(2):100918. (PMID: 36702124)
Nature. 2023 Sep;621(7979):592-601. (PMID: 37648855)
Nature. 2022 Feb;602(7898):671-675. (PMID: 35016199)
Nature. 2020 Oct;586(7830):572-577. (PMID: 32726802)
Signal Transduct Target Ther. 2021 Nov 3;6(1):378. (PMID: 34732694)
Sci Transl Med. 2022 Mar 9;14(635):eabl8124. (PMID: 35076282)
Methods Enzymol. 1997;276:307-26. (PMID: 27754618)
Nat Commun. 2017 Feb 13;8:14158. (PMID: 28194013)
BioDrugs. 2020 Feb;34(1):11-26. (PMID: 31686399)
Nat Struct Mol Biol. 2020 Sep;27(9):846-854. (PMID: 32661423)
Cell Rep. 2022 Jun 28;39(13):111004. (PMID: 35738279)
Cell Host Microbe. 2020 Sep 9;28(3):445-454.e6. (PMID: 32585135)
Biosaf Health. 2020 Dec;2(4):217-225. (PMID: 33196035)
J Nanobiotechnology. 2021 Jan 29;19(1):33. (PMID: 33514385)
Cell. 2022 Apr 14;185(8):1389-1401.e18. (PMID: 35344711)
Science. 2021 Feb 12;371(6530):. (PMID: 33436526)
Front Med. 2022 Apr;16(2):196-207. (PMID: 35253097)
Immunity. 2022 Aug 9;55(8):1501-1514.e3. (PMID: 35777362)
Cell. 2020 Oct 29;183(3):730-738.e13. (PMID: 32979942)
Nat Struct Mol Biol. 2020 Oct;27(10):950-958. (PMID: 32737466)
Annu Rev Biochem. 2013;82:775-97. (PMID: 23495938)
Curr Opin Biotechnol. 2011 Dec;22(6):868-76. (PMID: 21862310)
N Engl J Med. 2021 Jan 21;384(3):238-251. (PMID: 33332778)
Nat Commun. 2021 Aug 3;12(1):4676. (PMID: 34344900)
Nat Commun. 2023 May 16;14(1):2800. (PMID: 37193706)
Nano Today. 2022 Feb;42:101350. (PMID: 34840592)
Nature. 2021 Jul;595(7866):278-282. (PMID: 34098567)
Nature. 2022 Feb;602(7898):657-663. (PMID: 35016194)
Biochem Biophys Res Commun. 2021 Jan 29;538:192-203. (PMID: 33069360)
J Biomed Sci. 2022 Jan 4;29(1):1. (PMID: 34983527)
Acta Crystallogr D Biol Crystallogr. 2001 Oct;57(Pt 10):1373-82. (PMID: 11567148)
Cell. 2022 Aug 4;185(16):2952-2960.e10. (PMID: 35809570)
Nature. 2020 Aug;584(7821):443-449. (PMID: 32668443)
Acta Crystallogr D Biol Crystallogr. 2006 Aug;62(Pt 8):859-66. (PMID: 16855301)
Acta Crystallogr D Biol Crystallogr. 2004 Dec;60(Pt 12 Pt 1):2126-32. (PMID: 15572765)
Nat Commun. 2022 Dec 27;13(1):7957. (PMID: 36575191)
Signal Transduct Target Ther. 2023 May 10;8(1):197. (PMID: 37164987)
Acta Crystallogr D Biol Crystallogr. 2010 Feb;66(Pt 2):213-21. (PMID: 20124702)
Sci Adv. 2022 Jul 15;8(28):eabn4188. (PMID: 35857504)
Immunol Rev. 2022 Sep;310(1):76-92. (PMID: 35599305)
Antiviral Res. 2011 Dec;92(3):389-407. (PMID: 21939690)
Science. 2020 Dec 18;370(6523):1473-1479. (PMID: 33154106)
Nature. 2021 Nov;599(7885):465-470. (PMID: 34547765)
Cell Rep. 2021 Oct 19;37(3):109869. (PMID: 34644535)
Sci Transl Med. 2022 May 25;14(646):eabn1252. (PMID: 35412328)
Nature. 2020 May;581(7807):215-220. (PMID: 32225176)
Front Immunol. 2023 Feb 21;14:1111385. (PMID: 36895554)
Nat Commun. 2018 May 18;9(1):1996. (PMID: 29777099)
Cell. 2020 May 14;181(4):894-904.e9. (PMID: 32275855)
Nat Biotechnol. 2022 Dec;40(12):1845-1854. (PMID: 35864170)
Biosaf Health. 2020 Dec;2(4):226-231. (PMID: 32864605)
Cell. 2020 Jun 11;181(6):1436-1441. (PMID: 32531248)

0 (Single-Domain Antibodies)
0 (Epitopes)
0 (Spike Glycoprotein, Coronavirus)
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
0 (spike protein, SARS-CoV-2)

SARS-CoV-2 variants

Date Created: 20231130 Date Completed: 20231204 Latest Revision: 20231204

20231204

PMC10688893

10.1371/journal.ppat.1011804

38033141